VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug 21, 2013) - Pyng Medical Corp. (TSX VENTURE:PYT) (the "Company") today announced that its T-POD product recently participated in a comparative study among Pelvic Circumferential Compression Devices (PCCD's). The company's T-POD was ultimately chosen as the preferred device among a combination of 29 doctors, 11 medical students, and 10 emergency department nurses, with statistical significance (Emergency Department at the Leicester Royal Infirmary in Leicester, United Kingdom (UK)). Thirty nine participants (78%), p < 0.0001, reported that they preferred and, given the choice in the future, would select the T-POD.
Mark Hodge, President and Chief Executive Officer of Pyng Medical commented, "Pyng Medical strongly supports and advocates the use of PCCD's, per ATLS (Advanced Trauma Life Support) and TCCC (Tactical Combat Casualty Care) guidance, to stabilize traumatic disruption of the pelvis and to mitigate associated morbidity and mortality. It was therefore very gratifying for Pyng to have its T-POD chosen as the preferred PCCD, based upon the study conducted in Leicester, UK, as it highlighted the key aspects of T-POD; one-size-fits-all and being 100% radiolucent, thus allowing visualization of the pelvis during radiological investigations."
Mr. Hodge continued, "The Pyng brand is tied to 'Saving Lives in Seconds' and the T-POD product, in this study, shows exactly how we accomplish that. Pyng Medical believes, and I believe, that PCCD's can save lives among those inflicted with traumatic injury to the pelvis. I therefore hope that readers of this study will be motivated to use a PCCD, and choose T-POD, when faced with such injuries."
The results of the study conducted in Leicester, UK were published in the European Journal of Trauma and Emergency Surgery by D. J. Bryson, et al (Eur J Trauma Emerg Surg (2012) 38:439-442).
About Pyng Medical Corp.
Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.
Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.